Corcept Therapeutics Inc. (CORT), a commercial-stage company developing medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders, has a couple of catalysts to watch this year.
The lead drug candidate is Relacorilant, a non-steroidal, selective glucocorticoid receptor modulator that is being evaluated in a variety of serious disorders, including Cushing's syndrome, ovarian cancer and adrenal cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com